Institutional Biosafety Committee (IBC)
The IBC is posting the following revised document for review and comment:
The revised IBC Viral Vector Table aligns safety requirements for amphotropic murine retroviral vectors that express oncogenic or toxic inserts with safety requirements already in effect for lentiviral vectors expressing such inserts. Updated guidance in the viral vector table is highlighted in yellow.
Please note that the beginning of the template BSL-2+ biosafety manual contains a summary of how BSL-2+ differs from BSL-2. Also, when the IBC issues approval to work with biological agents at both BSL2 and BSL2+ in the same laboratory area, BSL2+ practices and PPE must be used for all biological experiments in that laboratory area while the BSL2+ work is active.
The NIH Guidelines Involving Recombinant or Synthetic Nucleic Acid Molecules, defines these nucleic acid molecules as:
(i) molecules that (a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids;
(ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e. synthetic nucleic acids, or
(iii) molecules that result from the replication of those described in (i) or (ii) above.
Infectious Agents are generally defined as risk group 2 agents and above (agents that can cause disease in healthy adult humans).
Use of Biologically Derived Toxins need only be reviewed by the IBC if the toxin is a select agent, or if the toxin is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight